Precision dosing of piperacillin/tazobactam in obese patients is compromised by sparse
information on target-site exposure. We aimed to evaluate the appropriateness of current …

Abstract Background and Objective Standard piperacillin–tazobactam (PT) dosing may be
suboptimal in obesity, but high-dose regimens have not been studied. We prospectively …

Study Objective To evaluate the steady‐state pharmacokinetic and pharmacodynamic
parameters of piperacillin in morbidly obese, surgical intensive care patients. Design Open …

The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …

Objective: To report pharmacokinetic alterations and optimal dosing of piperacillin/
tazobactam in an obese patient. Case Summary: A 39-year-old morbidly obese (weight 167 …

The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics
of piperacillin and tazobactam administered by prolonged infusion in obese patients …

Background Pharmacokinetic (PK) and pharmacodynamic (PD) data on perioperative
antibiotic prophylaxis or antibiotic therapy are rare in patients suffering from morbid obesity …

Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …

Ceftolozane/tazobactam is approved for treatment of complicated intra-abdominal infection
(cIAI) and complicated urinary tract infection (cUTI) with renal function-based dose …

The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …